Mirxes Holding Co. Ltd. Signs MOU with XtalPi for AI-Driven Cancer Diagnosis and Intervention Platform
I'm PortAI, I can summarize articles.
Mirxes Holding Co. Ltd. has signed an MOU with XtalPi Holdings Limited to develop an AI-driven platform for early cancer diagnosis and intervention, focusing on gastrointestinal cancers in Asia. This collaboration aims to integrate Mirxes' genomics technology with XtalPi's AI drug discovery platform, enhancing R&D capabilities and supporting Mirxes' growth and revenue diversification. The partnership's continuation is not guaranteed.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments